New Data on RYBREVANT ® (amivantamab-vmjw) in Combination with Lazertinib Show Early Activity in Patients with Non-Small Cell Lung Cancer Whose Disease Has Progressed After Both Osimertinib and Platinum-Based Chemotherapy
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary results from the Phase 1b CHRYSALIS-2 (NCT04077463) study evaluating RYBREVANT® (amivantamab-vmjw) in combination with lazertinib in the treatment of patients with non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib and platinum chemotherapy.[i] While previously reported results have demonstrated durable responses with RYBREVANT® in combination with...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANT ® (amivantamab-vmjw) Provides Higher Activity and Longer Duration of Response When Used in Combination with Lazertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer Who Have Failed Osimertinib
September 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new analysis from the CHRYSALIS (NCT02609776) study evaluating RYBREVANT® (amivantamab-vmjw) monotherapy and a combination regimen with lazertinib in advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations who progressed after osimertinib.[1] The analysis showed higher activity and longer duration of response (DOR) in patients treated with the combination therapy, demonstrating the potential benefit of targeting the extracellular (outer) and catal...
Source: Johnson and Johnson - September 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Fibrosis Progression Flies Below the Radar in Subclinical ILD Fibrosis Progression Flies Below the Radar in Subclinical ILD
The findings question the terms"subclinical/preclinical" interstitial lung disease, which may potentially lead to a suboptimal watchful waiting management, according to researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 17, 2021 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate can...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Phase 1 Results for RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
August 19, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANTTM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. The initial data showed anti-tumor activity in patients with METex14 mutations and a safety profile consistent with reported experience at the approved CHRYSALIS Phase 2 dose (RYBREVANTTM 1050 mg [
Source: Johnson and Johnson - August 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease CT Imaging May Help Distinguish COVID-19 From Interstitial Lung Disease
Computed tomography (CT) could be used to help distinguish COVID-19 from systemic sclerosis-related interstitial lung disease (SSc-ILD), researchers suggest.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - August 13, 2021 Category: Radiology Tags: Infectious Diseases News Source Type: news

New Biomarkers May Predict Course of ILD in Systemic Sclerosis New Biomarkers May Predict Course of ILD in Systemic Sclerosis
Radiographic assessment of interstitial lung disease (ILD) progression and proteins from bronchoalveolar lavage may independently provide better insight into prognoses of patients with systemic sclerosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Gene Variant Confirmed as Strong Predictor of Lung Disease in RA Gene Variant Confirmed as Strong Predictor of Lung Disease in RA
The MUC5B promoter variant is associated with a large increased risk of interstitial lung disease in patients with rheumatoid arthritis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 5, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Nintedanib Slows Interstitial Lung Disease in Patients With RA Nintedanib Slows Interstitial Lung Disease in Patients With RA
Nintedanib slowed progression of interstitial lung disease associated with rheumatoid arthritis in a subgroup analysis of a phase 3 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
Stabilization of lung function independent of the extent of quantitative radiographic interstitial lung disease or fibrosis at baseline (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 23, 2021 Category: Respiratory Medicine Tags: Dermatology, Pharmacy, Pulmonology, Radiology, Rheumatology, Journal, Source Type: news

Tocilizumab Preserves Lung Function in Early Systemic Sclerosis
FRIDAY, April 23, 2021 -- Tocilizumab prevents progression of interstitial lung disease in patients with early systemic sclerosis (SSc), according to a study recently published in Arthritis& Rheumatology. David Roofeh, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news

United Therapeutics Announces FDA Approval and Launch of Tyvaso(R) for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
First and only approved therapy in the United States for patients with PH-ILD, a serious, life-threatening disease with potentially more than 30,000 patients in need FDA approval based on data from the INCREASE clinical trial PH-ILD is the second FDA... Biopharmaceuticals, FDA, Product Launch United Therapeutics, Tyvaso, treprostinil, pulmonary hypertension (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 1, 2021 Category: Pharmaceuticals Source Type: news

United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.   The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 1, 2021 Category: Health Management Authors: Rebecca Cooper Source Type: news

United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.   The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 1, 2021 Category: Biotechnology Authors: Rebecca Cooper Source Type: news

United Therapeutics gets another FDA approval for pulmonary hypertension therapy
United Therapeutics (NASDAQ: UTHR) has received another Food and Drug Administration approval for Tyvaso more than a decade after the agency first approved the therapy for treatment of pulmonary arterial hypertension.   The FDA approved a supplemental new drug application for the use of Tyvaso Inhalation Solution, an inhaled form of the drug trepostinil, to increase exercise ability in patients with pulmonary hypertension resulting from interstitial lung disease (PH-ILD), United Therapeutics said… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - April 1, 2021 Category: Health Management Authors: Rebecca Cooper Source Type: news

Machine-learning predicts complications from CT-guided biopsy
Machine-learning models can predict whether a CT-guided transthoracic biops...Read more on AuntMinnie.comRelated Reading: AI reduces variability in breast density reporting Top 10 questions to ask when buying radiology AI software PET/CT guidance offers valuable approach to lung biopsies CT quantifies COVID-19 severity, ongoing conditions CT textures predict interstitial lung disease survival (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 15, 2021 Category: Radiology Source Type: news

Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease Study Clarifies Who Gets Post –COVID-19 Interstitial Lung Disease
A study of post –COVID-19 patients in the UK who developed severe lung inflammation after they left the hospital may provide greater clarity on which patients are most likely to have persistent lung dysfunction.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - March 4, 2021 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news

Tocilizumab May Improve Lung Function in Early Systemic Sclerosis Tocilizumab May Improve Lung Function in Early Systemic Sclerosis
Treatment with tocilizumab could stabilize or improve lung function in people with early interstitial lung disease associated with systemic sclerosis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 19, 2021 Category: Dermatology Tags: Rheumatology News Source Type: news

Lung Disease Raises Mortality Risk in Older RA Patients Lung Disease Raises Mortality Risk in Older RA Patients
RA-associated interstitial lung disease has been associated with worse survival rates as well as reduced quality of life, functional impairment, and increased health care use and costs.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

FDA grants priority review to Roche ’s Esbriet (pirfenidone) for unclassifiable interstitial lung disease
Basel, 21 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental New Drug Application (sNDA) and granted Priority Review for Esbriet® (pirfenidone) for the treatment of unclassifiable interstitial lung disease (UILD). The FDA is expected to make a decision on approval by May 2021.“Since its US approval, Esbriet has become a standard of care for people living with idiopathic pulmonary fibrosis. However, significant unmet need remains in fibrotic lung diseases, including unclassifiable interstitial lung disease ...
Source: Roche Investor Update - January 21, 2021 Category: Pharmaceuticals Source Type: news

Inhaled Treprostinil Beneficial in Pulmonary Hypertension
Exercise capacity improved, clinical worsening reduced for patients with pulmonary HTN due to interstitial lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - January 14, 2021 Category: Respiratory Medicine Tags: Cardiology, Pharmacy, Pulmonology, Journal, Source Type: news

Inhaled Treprostinil Beneficial in Pulmonary Hypertension
THURSDAY, Jan. 14, 2021 -- Inhaled treprostinil improves exercise capacity in patients with pulmonary hypertension due to interstitial lung disease, according to a study published online Jan. 13 in the New England Journal of Medicine. Aaron Waxman,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2021 Category: Pharmaceuticals Source Type: news

CT helps clinicians predict emphysema progression
The pattern of parenchymal emphysema on baseline CT scans forecasts progression...Read more on AuntMinnie.comRelated Reading: Deep-learning algorithm detects free air on CT images Machine learning boosts chest CT's performance CT textures predict interstitial lung disease survival COVID-19 patients face higher risk of barotrauma CT helps predict TAVR outcomes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 18, 2020 Category: Radiology Source Type: news

Study connects diabetes, air pollution to interstitial lung disease
(Michigan State University) People with pre-diabetes or diabetes who live in ozone-polluted areas may have an increased risk for an irreversible disease with a high mortality rate. These findings are especially important today in the midst of the COVID-19 pandemic, where there is a heightened concern for the convergence of health effects from air pollution and SARS-CoV-2 in susceptible populations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2020 Category: International Medicine & Public Health Source Type: news

Home oxygen therapy for adults with COPD and ILD: New ATS clinical practice guideline
(American Thoracic Society) The latest clinical practice guideline on home oxygen therapy addresses long-term and ambulatory oxygen therapy for adults with chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) and includes the most comprehensive review of the evidence of any oxygen guideline to date. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news

Interstitial Lung Disease (Interstitial Pneumonia)
Title: Interstitial Lung Disease (Interstitial Pneumonia)Category: Diseases and ConditionsCreated: 11/10/2014 12:00:00 AMLast Editorial Review: 11/12/2020 12:00:00 AM (Source: MedicineNet Lungs General)
Source: MedicineNet Lungs General - November 12, 2020 Category: Respiratory Medicine Source Type: news

Interstitial Lung Disease
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 12, 2020 Category: General Medicine Source Type: news

Pregnancy Can Be Safe With Interstitial Lung Disease Pregnancy Can Be Safe With Interstitial Lung Disease
Often women with ILD related to an autoimmune disease are advised to avoid conception or terminate their pregnancy. But the largest study to date on the subject draws more optimistic conclusions.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 8, 2020 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Interstitial lung disease associated with systemic sclerosis large burden
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2020 Category: Drugs & Pharmacology Source Type: news

InPedILD_trial_enrollment
Phase III InPedILD ™ trial enrolls first patient to evaluate nintedanib in pediatric population with fibrosing interstitial lung diseaseFirst-of-its-kind clinical trial in children and adolescents with fibrosing interstitial lung disease (ILD) initiated globallyThis new study builds on the Phase III INBUILD ® trial and approval of Ofev® in adult patients with fibrosing ILDs with a progressive phenotype1,2,3Global Phase III multicentre clinical trial is planned to be conducted in approximately 70 sites in 24 countries (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 12, 2020 Category: Research Source Type: news

Oxidative cross-linking of fibronectin confers protease resistance and inhibits cellular migration
The oxidation of tyrosine residues to generate o,o'-dityrosine cross-links in extracellular proteins is necessary for the proper function of the extracellular matrix (ECM) in various contexts in invertebrates. Tyrosine oxidation is also required for the biosynthesis of thyroid hormone in vertebrates, and there is evidence for oxidative cross-linking reactions occurring in extracellular proteins secreted by myofibroblasts. The ECM protein fibronectin circulates in the blood as a globular protein that dimerizes through disulfide bridges generated by cysteine oxidation. We found that cellular (fibrillar) fibronectin on the su...
Source: Signal Transduction Knowledge Environment - August 10, 2020 Category: Science Authors: Locy, M. L., Rangarajan, S., Yang, S., Johnson, M. R., Bernard, K., Kurundkar, A., Bone, N. B., Zmijewski, J. W., Byun, J., Pennathur, S., Zhou, Y., Thannickal, V. J. Tags: STKE Research Articles Source Type: news

ATS Issues Guide for Diagnosing Hypersensitivity Pneumonitis
Systematic approach developed for diagnosis of nonfibrotic, fibrotic HP in interstitial lung disease (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - August 5, 2020 Category: Respiratory Medicine Tags: Pathology, Pulmonology, Radiology, Allergy, Journal, Source Type: news

Drug-induced interstitial lung disease in breast cancer patients
(Compuscript Ltd) Drug-induced Interstitial Lung Disease in Breast Cancer Patients: A Lesson We Should Learn from Multi-Disciplinary IntegrationAnnouncing a new article publication for BIO Integration journal. In this case report the authors Zijun Zhao, Zhanghai He, Hongyan Huang, Jiewen Chen, Shishi He, Ailifeire Yilihamu and Yan Nie from Sun Yat-sen University, Guangzhou, China consider drug-induced interstitial lung disease in breast cancer patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 27, 2020 Category: International Medicine & Public Health Source Type: news

CT textures predict interstitial lung disease survival
Quantitative analysis of texture patterns on CT exams in interstitial lung...Read more on AuntMinnie.comRelated Reading: Which smokers seek out CT lung cancer screening? ECR 2020: COVID-19 greatest health threat since Spanish flu Dual-energy CT, CTA reveal COVID-19 lung patterns RSNA's COVID-19 chest CT classification system holds up AI helps distinguish COVID-19 from other pneumonias (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 23, 2020 Category: Radiology Source Type: news

EC_approval_nintedanib_ILD_PF
European Commission approves third nintedanib indication in pulmonary fibrosis1The approval is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).1The decision is based on the results of the INBUILD ® trial, the first study to evaluate patients with a broad range of chronic fibrosing interstitial lung diseases (ILDs) and a progressive disease behavior.2Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated inters...
Source: Boehringer Ingelheim Corporate News - July 15, 2020 Category: Research Source Type: news

Treprostinil Improves Walk Distance in Pulmonary Hypertension Treprostinil Improves Walk Distance in Pulmonary Hypertension
Exercise capacity increased after patients with pulmonary hypertension associated with interstitial lung disease were treated with the vasodilator for 16 weeks, new research shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 9, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

No Link Between Methotrexate, Interstitial Lung Disease in RA No Link Between Methotrexate, Interstitial Lung Disease in RA
Patients with rheumatoid arthritis are at elevated risk for interstitial lung disease, but methotrexate does not accentuate that risk and may be protective, new data show.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 11, 2020 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news

CHMP_opinion_nintedanib_ILD_PF
Boehringer Ingelheim receives positive CHMP opinion for a third nintedanib indication in pulmonary fibrosis1The opinion is for the treatment of adults with other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype beyond idiopathic pulmonary fibrosis (IPF).2The U.S. Food and Drug Administration (FDA) and Health Canada recently approved nintedanib as the first treatment for the same patient population.3,4Nintedanib is already approved in more than 80 countries for the treatment of idiopathic pulmonary fibrosis (IPF), and for systemic sclerosis-associated interstitial lung disease (SSc-ILD) in mo...
Source: Boehringer Ingelheim Corporate News - May 29, 2020 Category: Research Source Type: news

NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has published two new rapid COVID-19 guidelines. (Source: NHS Networks)
Source: NHS Networks - May 18, 2020 Category: UK Health Source Type: news

COVID-19 rapid guideline: interstitial lung disease [NG177], NICE
The guideline provides clinicians with advice on how to adjust care to reduce patients'exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic. The guideline highlights that bronchoscopy and pulmonary function tests have the potential to spread COVID-19 and they should only be carried out if the patient urgently needs them and if the results will have a direct impact on their care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 18, 2020 Category: Consumer Health News Source Type: news

European_Commission_approves_nintedanibSSc-ILD
European Commission approves nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD)Approval is based on the SENSCIS ® study which showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis-associated ILD (SSc-ILD)1Following the FDA ’s approval in September 2019, nintedanib in SSc-ILD has so far been approved in 15 countries including Canada, Japan and BrazilBeing the first and only approved treatment option available for people living with SSc-ILD, the approval constitutes a breakthrough in an area of high unmet need (Source: Boehring...
Source: Boehringer Ingelheim Corporate News - April 21, 2020 Category: Research Source Type: news

VIDA Completes Second Close Of Round C Financing
CORALVILLE, Iowa, April 15, 2020 -- (Healthcare Sales & Marketing Network) -- VIDA Diagnostics, Inc. ("VIDA"), the leader in AI-powered lung imaging analysis, received $2M from OSF Ventures, the corporate investment arm of OSF HealthCare, as a s... Devices, Venture Capital VIDA Diagnostics, COPD, asthma, interstitial lung disease, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 15, 2020 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung disease
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care ...
Source: Roche Investor Update - March 3, 2020 Category: Pharmaceuticals Source Type: news

CHMP_opinion_Nintedanib_SSc-ILD
Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease  Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD) in adults1Based upon positive SENSCIS ® trial results nintedanib was approved as the first and only therapy in the U.S. to slow the rate of decline in pulmonary function in patients with SSc-ILD2Nintedanib is already approved in more than 70 countries for the tre...
Source: Boehringer Ingelheim Corporate News - February 28, 2020 Category: Research Source Type: news